Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies

In brief

Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.

Key facts

Study ID
NCT07287189
Run by
Satellos Bioscience, Inc.
People needed
51
Starts
2025-12-08
Expected to finish
2027-06-30
Last updated by the study team
2026-07-31

Who can join

Age: 7 and older, up to 9. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.